Biguanide

Biguanide

SCHEMBL15969880

N=C(N)NC(=N)N.NCCNCCN

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.56
CA6 P23280 5/20 0.56
CA7 P43166 5/20 0.56
CA9 Q16790 5/20 0.56
CA14 Q9ULX7 5/20 0.56
CA5B Q9Y2D0 5/20 0.56
MEN1 O00255 2/20 0.56
RECQL P46063 2/20 0.56
KMT2A Q03164 2/20 0.56
CA2 P00918 4/20 0.53
CA4 P22748 4/20 0.53
CA5A P35218 4/20 0.53
LMNA P02545 3/20 0.53
CA3 P07451 3/20 0.53
ALOX15 P16050 3/20 0.53
TDP1 Q9NUW8 2/20 0.53
CA1 P00915 2/20 0.53
ALDH1A1 P00352 1/20 0.53
TP53 P04637 1/20 0.53
KDM4E B2RXH2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Spermidine SCHEMBL1286935 0.85 CA12 (0.64) CA12CA6CA7CA9CA14
Guanidine SCHEMBL28483885 0.85 CA12 (0.67) CA12CA6CA7CA9CA14
Trientine SCHEMBL9814189 0.82 CA12 (0.69) CA12CA6CA7CA9CA14
Biguanide SCHEMBL8719175 0.82 MAPT (0.36) LMNATDP1CYP1A2CYP2C19TSHR
SCHEMBL2489631 0.76 CA12 (0.71) CA12CA6CA7CA9CA14
SCHEMBL5314937 0.74 CA12 (1.00) CA12CA6CA7CA9CA14
SCHEMBL15381 0.74
Biguanide SCHEMBL18255803 0.74 MAPK1 (0.31)
Biguanide SCHEMBL8039 0.74
Thiourea SCHEMBL3345993 0.73 CA12 (0.67) CA12CA6CA7CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190142857-A1 METHODS TECREA LIMITED (GB) 2019-05-16 US claimed
US-20160089393-A1 COMPOSITION AND METHODS FOR COMBATING ANTIBACTERIAL RESISTANT BACTERIA BLUEBERRY THERAPEUTICS LIMITED (GB) 2016-03-31 US claimed
US-20140242097-A1 METHODS THE ROYAL VETERINARY COLLEGE (GB) 2014-08-28 US claimed
US-20190142857-A1 METHODS TECREA LIMITED (GB) 2019-05-16 US disclosed
US-10238683-B2 Methods for promoting entry of an agent into a cell THE ROYAL VETERINARY COLLEGE (GB) 2019-03-26 US disclosed
US-20160089393-A1 COMPOSITION AND METHODS FOR COMBATING ANTIBACTERIAL RESISTANT BACTERIA BLUEBERRY THERAPEUTICS LIMITED (GB) 2016-03-31 US disclosed
US-20140242097-A1 METHODS THE ROYAL VETERINARY COLLEGE (GB) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190142857-A1 METHODS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NUP210, PUF60 CA12 392/4885CA6 548/4885CA7 533/4885
US-20140242097-A1 METHODS NUP210, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PUF60 CA12 488/4885CA6 602/4885CA7 551/4885
US-10238683-B2 Methods for promoting entry of an agent into a cell H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NUP210, CCR10 CA12 375/4885CA6 449/4885CA7 516/4885
US-20160089393-A1 COMPOSITION AND METHODS FOR COMBATING ANTIBACTERIAL RESISTANT BACTERIA BPGM, PGM2, PMM2 CA12 1594/4885CA6 2155/4885CA7 1351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.